Phylo Launches Target Atlas for Drug Target Prioritization
Phylo Inc. announced in a press release the launch of Target Atlas, an application that uses hundreds of AI agents to collect and synthesize evidence for drug target prioritization. The company says the application can reduce evidence gathering from months to days while retaining records linked to their sources.
Target Atlas assesses genetics, expression, clinical activity, safety, tractability, biomarkers, competition and published research. Scientists can change evidence weights, compare how criteria affect rankings and review target profiles through interactive charts. A free public edition is available with a Biomni account.
Phylo also developed a Parkinson's edition with the Michael J. Fox Foundation for Parkinson's Research. It combines the foundation's target prioritization framework with evidence that can be continuously updated. An enterprise edition adds private data integration, governed Biomni deployments, target pair dashboards and AI scoring.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Nov 16 Healthcare AI spending grew 2.5x to $3.7B in 2026, Menlo Ventures says Nov 16 Remedy Robotics raises $62M Series B for AI-enabled endovascular robot Nov 16 Lumeris launches Tom Health to extend primary care with AI Nov 16 Flagship Pioneering commits £100M to London lab for AI-native companies Nov 16 Treat raises €3M pre-seed for AI-assisted intake in private healthcareLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Whitepaper
Tensordyne Napier: What If One Rack Could Do the Work of Nine?
Tensordyne
This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.
Read moreYou may also like
Phylo Brings Biomni Lab AI Agents to Bayer
Anthropic Reports Early Claude Results in Drug Development
Orakl Oncology Raises $34 Million to Predict Cancer Drug Response With AI
PharmaForceIQ Launches Share of Answer for Pharma AI Visibility
ALLOX Raises $10.5 Million for AI Drug Discovery Platform
Daily AI Brief: the AI news that matters, in your inbox.